Clinical validation of the dried blood spot analysis for antituberculosis drugs

Clinical validation of the dried blood spot analysis for antituberculosis drugs - DBS analysis of anti-TB drugs

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON34891

Enrollment

Registered

2010-10-08

Start date

2010-10-13

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Blood concentration of anti TB drugs

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Adult (>18 years old) - TB-patient who using at least one of the following drugs: Isoniazid, Pyrazinamide, Rifampicin, Ethambutol, clarithromycin, Amikacin, Kanamycin, Moxifloxacin, Linezolid - TB-patient who is scheduled for routine TDM by the doctor. - written informed consent

Exclusion criteria

Exclusion criteria: Patients with serious bleeding disorder

Design outcomes

Primary

Measure	Time frame
The correlation of laboratory analysis results from DBS method to conventional method	—

Secondary

Measure	Time frame
The influence of origin of the bloodsample (finger prick or venous blood) on the concentration of the drug and its effect on DBS results	—

Countries

Netherlands

Outcome results